Journal of Proteomics & Bioinformatics
Open Access

Marc Riviere

Biography

Marc Riviere is an experienced executive with a track record in successfully building and managing clinical programs, his expertise encompasses all aspects of drug development in different clinical indications from pre-clinical development to post marketing surveillance. At TVM Capital Life Science, he focuses on evaluation of deal opportunities and investment management for therapeutics. He also works closely with the firm’s strategic partner Eli Lilly & Co. and its drug development division Chorus. He also serves on the board of publicly listed (Euronext) Cerenis Therapeutics, Toulouse, France, Ann Arbor, USA. Prior to joining TVM Capital Life Science, Marc was Vice-President, Axcan Pharma Inc., in charge of Clinical Development, Medical Affairs and Pharmacovigilance and a member of the Axcan Licensing Committee. He also served as Senior Vice President, Clinical Development at Caprion Pharmaceuticals, Chief Medical Officer for Bioniche Life Sciences Inc., Managing Director of Xenon Genetics Inc., Vice President of Clinical Affairs, Aeterna Labs and Executive Vice President and Regional Director, Quintiles Inc. He was also member of the Guideline Review Committee of the Canadian Co-ordination Office of Health Technology Assessment. Marc received his Tropical Disease Medicine Certification from Université Bordeaux II, France and Medicine Doctorate from Université Paul Sabatier, Toulouse, France, and has over fifty publications and scientific communications to his credit.

Research Interest

Clinical Development, Pharmaceutical Industry, Gastroenterology, Medical Affairs, Clinical Research, Drug Development, Clinical Trials

Relevant Topics